Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk
The Journal of Infectious Diseases · 20.12.2023 · 228 (12) · 1667-1674
DOI: 10.1093/infdis/jiad324 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 11.08.2023. Verfasst von Dimitrios Paraskevis und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hygiene, Epidemiology, and Medical Statistics, Medical School, National and Kapodistrian University of Athens. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Public Health Organization, Greece.
Abstract (Originalsprache)
Background
Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable.
Methods
The impact of each drug was determined via comparisons with age-matched control groups of patients positive for SARS-CoV-2 who did not receive oral antiviral therapy.
Results
Administration of molnupiravir significantly reduced the risk of hospitalization (odds ratio [OR], 0.40; P < .001) and death (OR, 0.31; P < .001) among these patients based on data adjusted for age, previous SARS-CoV-2 infection, vaccination status, and time elapsed since the most recent vaccination. The reductions in risk were most profound among elderly patients (≥75 years old) and among those with high levels of drug adherence. Administration of nirmatrelvir/ritonavir also resulted in significant reductions in the risk of hospitalization (OR, 0.31; P < .001) and death (OR, 0.28; P < .001). Similar to molnupiravir, the impact of nirmatrelvir/ritonavir was more substantial among elderly patients and in those with high levels of drug adherence.
Conclusions
Collectively, these real-world findings suggest that although the risks of hospitalization and death due to COVID-19 have been reduced, antivirals can provide additional benefits to members of highly vulnerable patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hygiene, Epidemiology, and Medical Statistics, Medical School, National and Kapodistrian University of Athens.
- National Public Health Organization.
- Second Respiratory Medicine Department, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens.
- First Department of Critical Care Medicine and Pulmonary Services, Evaggelismos Hospital, Medical School, National and Kapodistrian University of Athens.
- Second Department of Medicine and Infectious Diseases, HYGEIA Hospital, Marousi.
- National Agency for Quality Assurance in Health, Athens.
ORCID-Profile: Dimitrios Paraskevis, Elias Mossialos
Förderung
- National Public Health Organization, Greece
Zitieren
APA
Paraskevis, D., Gkova, M., Mellou, K., Gerolymatos, G., Psalida, N., Gkolfinopoulou, K., Kostaki, E. G., Loukides, S., Kotanidou, A., Skoutelis, A., Thiraios, E., Saroglou, G., Zografopoulos, D., Filippou, D., Mossialos, E., Zaoutis, T., Gaga, M., Tsiodras, S., & Antoniadou, A. (2023). Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk. The Journal of Infectious Diseases, 228(12), 1667-1674. https://doi.org/10.1093/infdis/jiad324
Vancouver
Paraskevis D, Gkova M, Mellou K, Gerolymatos G, Psalida N, Gkolfinopoulou K, et al. Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk. The Journal of Infectious Diseases. 2023;228(12):1667-1674. doi:10.1093/infdis/jiad324
BibTeX
@article{Paraskevis2023,
author = {Paraskevis, Dimitrios and Gkova, Maria and Mellou, Kassiani and Gerolymatos, Gerasimos and Psalida, Naya and Gkolfinopoulou, Kassiani and Kostaki, Evangelia-Georgia and Loukides, Stylianos and Kotanidou, Anastasia and Skoutelis, Athanasios and Thiraios, Eleftherios and Saroglou, Georgios and Zografopoulos, Dimitrios and Filippou, Dimitrios and Mossialos, Elias and Zaoutis, Theoklis and Gaga, Mina and Tsiodras, Sotirios and Antoniadou, Anastasia},
title = {Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk},
journal = {The Journal of Infectious Diseases},
year = {2023},
volume = {228},
number = {12},
pages = {1667--1674},
doi = {10.1093/infdis/jiad324}
}
EUVIMED